Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations analyze observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://eddieu108zei3.qodsblog.com/profile